Telomere length (TL) is a biomarker of cell aging, and its shortening has been linked to several age-related diseases. In Alzheimer’s disease (AD), telomere shortening has been associated with neuroinflammation and oxidative stress. The majority of studies on TL in AD were based on leucocyte DNA, with little information about its status in the central nervous system. In addition to other neuroprotective effects, lithium has been implicated in the maintenance of TL. The present study aims to determine the effect of chronic lithium treatment on TL in different regions of the mouse brain, using a triple-transgenic mouse model (3xTg-AD). Eighteen transgenic and 22 wild-type (Wt) male mice were treated for eight months with chow containing 1.0 g (Li1) or 2.0 g (Li2) of lithium carbonate/kg, or standard chow (Li0). DNA was extracted from parietal cortex, hippocampus and olfactory epithelium and TL was quantified by real-time PCR. Chronic lithium treatment was associated with longer telomeres in the hippocampus (Li2, p = 0.0159) and in the parietal cortex (Li1, p = 0.0375) of 3xTg-AD compared to Wt. Our findings suggest that chronic lithium treatment does affect telomere maintenance, but the magnitude and nature of this effect depend on the working concentrations of lithium and characteristics of the tissue. This effect was observed when comparing 3xTg-AD with Wt mice, suggesting that the presence of AD pathology was required for the lithium modulation of TL.
ShayJW, WrightWE (2007) Hallmarks of telomeres in ageing research. J Pathol211, 114–123.
3.
FichtmanB, HarelA (2014) Stress and aging at the nuclear gateway. Mech Ageing Dev135, 24–32.
4.
ManAL, GichevaN, NicolettiC (2014) The impact of ageing on the intestinal epithelial barrier and immune system. Cell Immunol289, 112–118.
5.
ChiuCL, HearnNL, PaineD, SteinerN, LindJM (2016) Does telomere shortening precede the onset of hypertension in spontaneously hypertensive mice?Twin Res Hum Genet19, 422–429.
6.
YehJ-K, WangC-Y (2016) Telomeres and telomerase in cardiovascular diseases. Genes (Basel)7, 58.
7.
AstrupAS, TarnowL, JorsalA, LajerM, NzietchuengR, BenetosA, RossingP, ParvingHH (2010) Telomere length predicts all-cause mortality in patients with type 1 diabetes. Diabetologia53, 45–48.
8.
Murillo-OrtizB, Albarrán-TamayoF, Arenas-ArandaD, Benítez-BribiescaL, Malacara-HernándezJ, Martínez-GarzaS, Hernández-GonzálezM, SolorioS, Garay-SevillaM, Mora-VillalpandoC (2012) Telomere length and type 2 diabetes in males, a premature aging syndrome. Aging Male15, 54–58.
9.
HonigLS, KangMS, SchupfN, LeeJH, MayeuxR (2012) Association of shorter leukocyte telomere repeat length with dementia and mortality. Arch Neurol69, 1332–1339.
10.
HonigLS, SchupfN, LeeJH, TangMX, MayeuxR (2006) Shorter telomeres are associated with mortality in those with APOE ɛ4 and dementia. Ann Neurol60, 181–187.
RagnoM, PianeseL, PinelliM, SilvestriS, CacchiòG, Di MarzioF, ScarcellaM, CorettiF, AltamuraF, MonticelliA, CastaldoI (2011) Shorter telomeres in patients with cerebral autosomal dominant arteriopathy and leukoencephalopathy (CADASIL). Neurogenetics12, 337–343.
19.
CsernanskyJG, WangL, SwankJ, MillerJP, GadoM, McKeelD, MillerMI, MorrisJC (2005) Preclinical detection of Alzheimer’s disease: Hippocampal shape and volume predict dementia onset in the elderly. Neuroimage25, 783–792.
20.
Gunten AVon, KövariE, BussièreT, RivaraCB, GoldG, BourasC, HofPR, GiannakopoulosP (2006) Cognitive impact of neuronal pathology in the entorhinal cortex and CA1 field in Alzheimer’s disease. Neurobiol Aging27, 270–277.
21.
ChantalS, LabelleM, BouchardRW, BraunCMJ, BoulangerY (2002) Correlation of regional proton magnetic resonance spectroscopic metabolic changes with cognitive deficits in mild Alzheimer disease. Arch Neurol59, 955.
22.
KantarciK, JackCR, XuYC, CampeauNG, O’BrienPC, SmithGE, IvnikRJ, BoeveBF, KokmenE, TangalosEG, PetersenRC (2000) Regional metabolic patterns in mild cognitive impairment and Alzheimer’s disease: A 1H MRS study. Neurology55, 210–217.
23.
HuY, DingW, ZhuX, ChenR, WangX (2016) Olfactory dysfunctions and decreased nitric oxide production in the brain of human P301L tau transgenic mice. Neurochem Res41, 722–730.
24.
Lachén-MontesM, González-MoralesA, de MorentinXM, Pérez-ValderramaE, AusínK, ZelayaMV, SernaA, AsoE, FerrerI, Fernández-IrigoyenJ, SantamaríaE (2016) An early dysregulation of FAK and MEK/ERK signaling pathways precedes the β-amyloid deposition in the olfactory bulb of APP/PS1 mouse model of Alzheimer’s disease. J Proteomics148, 149–158.
25.
LukensJN, Van DeerlinV, ClarkCM, XieSX, JohnsonFB (2009) Comparisons of telomere lengths in peripheral blood and cerebellum in Alzheimer’s disease. Alzheimers Dement5, 463–469.
26.
ThomasP, O’ CallaghanNJ, FenechM (2008) Telomere length in white blood cells, buccal cells and brain tissue and its variation with ageing and Alzheimer’s disease. Mech Ageing Dev129, 183–190.
27.
GeddesJR, MiklowitzDJ (2013) Treatment of bipolar disorder. Lancet381, 1672–1682.
28.
ChiuC-T, ChuangD-M (2011) Neuroprotective action of lithium in disorders of the central nervous system. Zhong Nan Da Xue Xue Bao Yi Xue Ban36, 461–476.
CaminsA, VerdaguerE, JunyentF, Yeste-VelascoM, PelegríC, VilaplanaJ, PallásM (2009) Potential mechanisms involved in the prevention of neurodegenerative diseases by lithium. CNS Neurosci Ther15, 333–344.
31.
De-Paula V deJ, KerrDS, de CarvalhoMPF, SchaefferEL, TalibLL, GattazWF, ForlenzaOV (2015) Long-term lithium treatment increases cPLA2 and iPLA2 activity in cultured cortical and hippocampal neurons. Molecules20, 19878–19885.
32.
ForlenzaOV, De PaulaVJ, MacHado-VieiraR, DinizBS, GattazWF (2012) Does lithium prevent Alzheimer’s disease?Drugs and Aging29, 335–342.
33.
MorrisG, BerkM (2016) The putative use of lithium in Alzheimer’s disease. Curr Alzheimer Res13, 853–861.
34.
De-PaulaVJ, GattazWF, ForlenzaOV (2016) Long-term lithium treatment increases intracellular and extracellular brain-derived neurotrophic factor (BDNF) in cortical and hippocampal neurons at subtherapeutic concentrations. Bipolar Disord18, 692–695.
35.
NunesMA, VielTA, BuckHS (2013) Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer’s disease. Curr Alzheimer Res10, 104–107.
36.
MartinssonL, WeiY, XuD, MelasPA, MathéAA, SchallingM, LavebrattC, BacklundL (2013) Long-term lithium treatment in bipolar disorder is associated with longer leukocyte telomeres. Transl Psychiatry3, e261.
37.
ChuangD-M, WangZ, ChiuC-T (2011) GSK-3 as a target for lithium-induced neuroprotection against excitotoxicity in neuronal cultures and animal models of ischemic stroke. Front Mol Neurosci4, 15.
38.
ZhangY, TohL, LauP, WangX (2012) Human telomerase reverse transcriptase (hTERT) is a novel target of the Wnt/β-catenin pathway in human cancer. J Biol Chem287, 32494–32511.
39.
Soeiro-de-SouzaMG, TeixeiraAL, MateoEC, ZanettiMV, RodriguesFG, de PaulaVJ, BezerraJF, MorenoRA, GattazWF, Machado-VieiraR (2014) Leukocyte telomerase activity and antidepressant efficacy in bipolar disorder. Eur Neuropsychopharmacol24, 1139–1143.
40.
MontpetitA, AlhareeriAA, MontpetitM, StarkweatherAR, ElmoreLW, FillerK, MohanrajL, BurtonCW, MenziesVS, LyonDE, Jackson-CookCK (2015) Telomere length: A review of methods for measurement. Nurs Res63, 289–299.
41.
CallicottRJ, WomackJE (2006) Real-time PCR assay for measurement of mouse telomeres. Comp Med56, 17–22.
O’CallaghanNJ, FenechM (2011) A quantitative PCR method for measuring absolute telomere length. Biol Proced Online13, 3.
44.
OzturkM, LiY, TergaonkarV (2017) Current insights to regulation and role of telomerase in human diseases. Antioxidants6, 17.
45.
PolhoGB, De-PaulaVJ, CardilloG, dos SantosB, KerrDS (2015) Leukocyte telomere length in patients with schizophrenia: A meta-analysis. Schizophr Res165, 195–200.
46.
HartwigFP, NedelF, CollaresTV, TarquinioSBC, NörJE, DemarcoFF (2012) Telomeres and tissue engineering: The potential roles of TERT in VEGF-mediated angiogenesis. Stem Cell Rev8, 1275–1281.
47.
PhielCJ, WilsonCA, LeeVM-Y, KleinPS (2003) GSK-3alpha regulates production of Alzheimer’s disease amyloid-beta peptides. Nature423, 435–439.
HimmelsteinDS, WardSM, LanciaJK, PattersonKR, BinderLI (2012) Tau as a therapeutic target in neurodegenerative disease. Pharmacol Ther136, 8–22.
50.
HuangEJ, ReichardtLF (2001) Neurotrophins: Roles in neuronal development and function. Annu Rev Neurosci24, 677–736.
51.
Machado-VieiraR, YuanP, BrutscheN, DiazGranadosN, LuckenbaughD, ManjiHK, ZarateCA (2009) Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry70, 1662–1666.
52.
FuW, LuC, MattsonMP (2002) Telomerase mediates the cell survival-promoting actions of brain-derived neurotrophic factor and secreted amyloid precursor protein in developing hippocampal neurons. J Neurosci22, 10710–10719.
53.
HuangEJ, ReichardtLF (2003) Trk receptors: Roles in neuronal signal transduction. Annu Rev Biochem72, 609–642.
54.
AlmeidaRD, ManadasBJ, MeloCV, GomesJR, MendesCS, GrãosMM, CarvalhoRF, CarvalhoAP, DuarteCB (2005) Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways. Cell Death Differ12, 1329–1343.
55.
NguyenN, LeeSB, LeeYS, LeeKH, AhnJY (2009) Neuroprotection by NGF and BDNF against neurotoxin-exerted apoptotic death in neural stem cells are mediated through TRK receptors, activating PI3-kinase and MAPK pathways. Neurochem Res34, 942–951.
56.
BermudezY, YangH, ChengJQ, KrukPA (2008) Pyk2/ERK 1/2 mediate Sp1- and c-Myc-dependent induction of telomerase activity by epidermal growth factor. Growth Factors26, 1–11.
57.
KawauchiK, IhjimaK, YamadaO (2005) IL-2 increases human telomerase reverse transcriptase activity transcriptionally and posttranslationally through phosphatidylinositol 3’-kinase/Akt, heat shock protein 90, and mammalian target of rapamycin in transformed NK cells. J Immunol174, 5261–5269.
58.
KimuraA, OhmichiM, KawagoeJ, KyoS, MabuchiS, TakahashiT, OhshimaC, Arimoto-IshidaE, NishioY, InoueM, KurachiH, TasakaK, MurataY (2004) Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines. Oncogene23, 4505–4515.
59.
MaidaY, KyoS, KanayaT, WangZ, YatabeN, TanakaM, NakamuraM, OhmichiM, GotohN, MurakamiS, InoueM (2002) Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway. Oncogene21, 4071–4079.
60.
De-PaulaVJ, KerrDS, ScolaG, GattazWF, ForlenzaOV (2016) Lithium distinctly modulates the secretion of pro- and anti- inflammatory interleukins in co-cultures of neurons and glial cells at therapeutic and sub-therapeutic concentrations. Curr Alzheimer Res13, 848–852.
61.
ConnerJM, LauterbornJC, YanQ, GallCM, VaronS (1997) Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat cns: Evidence for anterograde axonal transport. J Neurosci17, 2295–2313.
62.
BothaM, GraceL, BugarithK, RussellVA, KiddM, SeedatS, HemmingsSMJ (2012) The impact of voluntary exercise on relative telomere length in a rat model of developmental stress. BMC Res Notes5, 697.
63.
ManayeKF, MoutonPR, XuG, DrewA, LeiDL, SharmaY, RebeckGW, TurnerS (2013) Age-related loss of noradrenergic neurons in the brains of triple transgenic mice. Age (Omaha)35, 139–147.
64.
SchaefferEL, CatanoziS, WestMJ, GattazWF (2017) Stereological investigation of the CA1 pyramidal cell layer in untreated and lithium-treated 3xTg-AD and wild-type mice. Ann Anat209, 51–60.
